Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Next Previous
Trial Profile

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Alcoholic hepatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Vital Therapies

    • Most Recent Events

    • 20 Oct 2015 According to ClinicalTrials.gov, this study has been terminated because of results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated.
    • 17 Oct 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
    • 30 Jul 2015 According to a Vital Therapies media release, as of July 29, 2015, the eighteenth subject has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top